Iovance Non Current Liabilities Total from 2010 to 2024
| IOVA Stock | USD 10.15 0.20 1.93% |
Non Current Liabilities Total | First Reported 2012-12-31 | Previous Quarter 106.6 M | Current Value 102.1 M | Quarterly Volatility 38.1 M |
Check Iovance Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iovance Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 34.8 M, Interest Expense of 3.6 M or Selling General Administrative of 30.7 M, as well as many indicators such as Price To Sales Ratio of 1.3 K, Dividend Yield of 0.1 or PTB Ratio of 3.11. Iovance financial statements analysis is a perfect complement when working with Iovance Biotherapeutics Valuation or Volatility modules.
Iovance | Non Current Liabilities Total |
Latest Iovance Biotherapeutics' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Iovance Biotherapeutics over the last few years. It is Iovance Biotherapeutics' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iovance Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Iovance Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 25,998,307 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 145.60 | |
| Mean Deviation | 33,753,742 | |
| Median | 0.00 | |
| Standard Deviation | 37,852,505 | |
| Sample Variance | 1432.8T | |
| Range | 89.7M | |
| R-Value | 0.85 | |
| Mean Square Error | 429.4T | |
| R-Squared | 0.72 | |
| Significance | 0.000061 | |
| Slope | 7,190,501 | |
| Total Sum of Squares | 20059.4T |
Iovance Non Current Liabilities Total History
About Iovance Biotherapeutics Financial Statements
Iovance Biotherapeutics stakeholders use historical fundamental indicators, such as Iovance Biotherapeutics' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Iovance Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Iovance Biotherapeutics' assets and liabilities are reflected in the revenues and expenses on Iovance Biotherapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Iovance Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 85.4 M | 89.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Iovance Stock
When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock:Check out the analysis of Iovance Biotherapeutics Correlation against competitors. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.67) | Revenue Per Share 0.124 | Quarterly Revenue Growth 129.697 | Return On Assets (0.33) | Return On Equity (0.65) |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.